linjc16/ctgov huggingface dataset:
Patients With Acute Renal Failure During Severe COVID-19

Study Overview
=================
Brief Summary
-----------------
The occurrence of renal failure during severe forms of COVID-19 is common (20-35% of patients treated in intensive care) and associated with an unfavorable short-term prognosis, but the medium-term renal outcome is not is not known. The aim of the study is to establish the frequency of chronic kidney failure after AKI KDIGO 2 and 3 occurring during severe COVID-19 in intensive care.

Official Title
-----------------
Renal Assessment of Patients With Acute Renal Failure During Severe COVID-19

Conditions
-----------------
Renal Failure Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subject (≥18 years old) Subject hospitalized in an intensive care unit, Strasbourg, Nancy or Reims hospitals, for severe COVID-19 between February 1, 2020 and July 31, 2020. Having presented acute renal failure KDIGO 2 (assessed on a doubling of serum creatinine compared to the patient's reference values) or 3 (serum creatinine greater than 3 times the patient's reference, or anuria, or any recourse to extra-purification renal) Having left hospital alive after initial treatment for COVID-19 Subject not having expressed his opposition, after information, to the reuse of his data for the purposes of this research. Exclusion criteria: Subject having expressed opposition to participating in the study Subject under guardianship or guardianship Subject under safeguard of justice

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of renal development in patients with acute renal failure during severe COVID-19 |  | Files analysed retrospectively from February 01, 2020 to July 31, 2020 will be examined] | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, SARS-COV-2, Renal failure
Low-profile Visualized Intraluminal Support -HUD

Study Overview
=================
Brief Summary
-----------------
The MicroVention Low-profile Visualized Intraluminal Support (LVIS*) Device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck (neck greater than or equal to 4 or a dome to neck ratio less than two), intracranial, saccular aneurysms arising from a parent vessel with a diameter of greater than or equal to 2.5mm and less than or equal to 4.5mm.

Detailed Description
-----------------
Wide neck aneurysms are very difficult to treat both surgically and endovascularly with clipping or coiling. The availability of this neurovascular flow diverter as a Humanitarian Use Device has provided an additional approach to aneurysm occlusion using endovascular techniques.

Official Title
-----------------
MicroVention Low-profile Visualized Intraluminal Support (LVIS*) or LVIS Jr Humanitarian Use Device (LVIS HUD)

Conditions
-----------------
Giant Wide Necked Aneurysms

Intervention / Treatment
-----------------
* Device: Low Profile Visualized Intraluminal Support Device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Wide neck (neck greater than or equal to 4 or a dome to neck ratio less than two),Intracranial, saccular aneurysm arising from a parent vessel with a diameter of greater than or equal to 2.5mm and less than or equal to 4.5mm.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients

Study Overview
=================
Brief Summary
-----------------
In this study we tried to elucidate the factors associated with the development of a rapid cycling course in bipolar disorder patients, in a prospective and longitudinal design, and the role of antidepressants. The identification of risk factors is extremely relevant from the clinical point of view. We hypothesized that rapid cycling bipolar disorder is associated with more chronicity, poor outcome, and more antidepressant prescription.

Official Title
-----------------
Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients

Conditions
-----------------
Bipolar Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bipolar I and II disorder patients according to DSM-IV criteria Exclusion Criteria: Major medical comorbidities, voluntary drop-out from study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rapid Cycling Group<br>Patients who develop a rapid cycling course during the follow-up period. | |
| Non Rapid Cycling Group<br>Patients who do not develop a rapid cycling course during the follow-up period. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients who develop rapid cycling |  | 8 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors associated with the development of a rapid cycling course in bipolar disorder patients |  | 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rapid cycling
Genetics of Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Genetic etiology in schizophrenia is widely accepted. However, many chromosomal sites were shown to characterize the families of patients with schizophrenia. This is probably due to the high genetic heterogenity of this illness. Thus, it is important to investigate the genetic factor in relatively genetically homogenous populations. Many studies have indicate that Ashkenazy Jews show relative gentic homogenity. Indeed, the genes responsible for most Mendelian disorders of Jewish peoples have been identified. The study will apply genome-wide mutation screening methods to identify candidate allells in subjects of Ashkenazi Jewish ancestry with multiplex schizophrenia.

Official Title
-----------------
Genetics of Schizophrenia

Conditions
-----------------
Schizophrenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18+; Meet DSM-IV criteria for Schizophrenia; At least one first-degree relative who Meet DSM-IV criteria for Schizophrenia; Can sign the informed consent form. Exclusion Criteria: Patients suffering from terminal or incurabale disease; Minors, incompetents

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, genetics, family, multiplex, haplotypes
Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
WP1.1. PK/PD target attainment: Plasma exposure, Excretion via urine & ELF exposure; WP1.2. Predictive dosing algorithm; WP1.3. ECMO subset

Detailed Description
-----------------
First, the investigators will document exposure to meropenem in plasma and epithelial lining fluid. Moreover excretion in urine will be documented. Second, the investigators will try to identify risk factors for not attaining PK/PD target. Based on significant predictors for target non attainment a predictive dosing algorithm will be constructed. Finally in a small subset of ECMO patients PK exposure will be explored.

Official Title
-----------------
Optimization of PK/PD Target Attainment for Meropenem in Critically Ill Patients With Sepsis

Conditions
-----------------
Critical Illness, Pharmacokinetics

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Severe sepsis or septic shock Admitted to an ICU ward Treated with meropenem Exclusion Criteria: eGFR(CKD-EPI) < 70ml/min/1.73m² Renal replacement therapy Pregnancy DNR code 1-3

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factors for target non attainment | risk factors will be assessed by comparing patients who attain target vs. those who don't | on day of sampling | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pharmacokinetics, Meropenem, Critical illness, Capillary leak, Augmented renal clearance
Taiwanese People's Willingness to Participate in Cancer Screening: Colon, Oral Cavity, Breast, and Cervical Cancer Screening

Study Overview
=================
Brief Summary
-----------------
Cancer Screening is necessary for promoting cancer prevention in the area of public health. The Department of Health, Executive Yuan of the Republic of China has expanded and included colon cancer screening, oral cavity cancer screening, breast cancer screening, and cervical cancer screening in national-wide preventive healthcare services. However, most of the Taiwanese do not have the concepts of what cancer screening is and regular participation of cancer screening. This will easily cause their neglect of quality of personal healthcare and habits of cancer screening. Recently, in order to reach the national goal of cancer prevention, the parallel methods, multi-promotion for reinforcing concepts and free cancer screening, have been utilized to cultivate Taiwanese people's active participation of cancer screening. Therefore, this study will use health service utilization model to investigate Taiwanese people's concepts of cancer-related knowledge and the major causes of low participation of cancer screening. In order to investigate Taiwanese people's health service utilization model and quality of health life, this study first review the related regulations and screening rates of cancer prevention, including cancers of colon, oral cavity, breast, and cervical, in Taiwan. In addition, the structured questionnaire will be conducted to collect, investigate, and analyze the relationship between the willingness of participating the aforementioned cancer screening and personal characteristics, quality of health life, medical history, and concepts of cancer, etc. It is expected that the results of this study will provide accurate and effective promotions of cancer screening to medical institutions and medical affairs to reinforce the concepts of participation for raising the rates of cancer screening; furthermore, to awaken Taiwanese people's crucial awareness of early treatment improves the chances of recovery on cancer.

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cases who are willing to answer the questionnaire Exclusion Criteria: Cases who are not willing to answer the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients, Family, Community member | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer Screening, health service utilization model, quality of health life
Impact of a Non-Drug Choice on Cocaine Reinforcement

Study Overview
=================
Brief Summary
-----------------
Cocaine-use disorders continue to be a significant public health concern, yet no effective medications have been identified. The goal of this study is to establish a research platform for the development of medications for treatment of cocaine abuse and dependence. This study will incorporate self-administration procedures and a non-drug alternative reinforcer, which is hypothesized to reduce the reinforcing effects of cocaine.

Official Title
-----------------
Impact of a Non-Drug Choice on Cocaine Reinforcement

Conditions
-----------------
Cocaine Dependence

Intervention / Treatment
-----------------
* Drug: Cocaine
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cocaine dependence, otherwise healthy Exclusion Criteria: Laboratory results outside of clinically acceptable ranges, history of or current serious physical or psychiatric disease

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low Value Alternative Reinforcer<br>A low value reinforcer will be made available as an alternative to cocaine and placebo. | Drug: Cocaine<br>* Three active doses of cocaine will be made available for self-administration during experimental sessions.<br>Drug: Placebo<br>* Placebo cocaine will be made available for self-administration during experimental sessions.<br>|
| Experimental: Medium Value Reinforcer<br>A medium value reinforcer will be made available as an alternative to cocaine and placebo. | Drug: Cocaine<br>* Three active doses of cocaine will be made available for self-administration during experimental sessions.<br>Drug: Placebo<br>* Placebo cocaine will be made available for self-administration during experimental sessions.<br>|
| Experimental: High Value Reinforcer<br>A high value reinforcer will be made available as an alternative to cocaine and placebo. | Drug: Cocaine<br>* Three active doses of cocaine will be made available for self-administration during experimental sessions.<br>Drug: Placebo<br>* Placebo cocaine will be made available for self-administration during experimental sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative | The reinforcing effects of cocaine were determined using a modified progressive ratio procedure in which subjects made 9 choices between each available cocaine dose and one of three money alternatives. | 9 choice trials per cocaine dose level with each trial separated by 30 minutes |
Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is the descriptive analysis of incidence & severity of side effects & reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.

Detailed Description
-----------------
750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.

Conditions
-----------------
Chronic Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patient age > 18 Patient is treated with transdermal Buprenorphine The patient is able to answer the patient's survey & has an estimated overall survival of minimum 6 months The patient gives his/her informed, written consent to participate in the study Exclusion Criteria Patient Age < 18 Patient has less than 6 months survival expectancy Patient is unable to answer the patient survey for whatever reason in any feasible form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence and severity of side effects | Descriptive analysis of incidence and severity of side effects and reasons for discontinuation with Buprenorphine patches. Safety Issue - No | patients observed for 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment patterns | Insight into patient profiles treatment patterns and satisfaction. | patients observed for 6 months |
Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients

Study Overview
=================
Brief Summary
-----------------
Evaluation of the effectiveness and the costs of a quantitative and qualitative nutritional supplementation in elderly patients

Official Title
-----------------
Effectiveness and Cost of a Quantitative and Qualitative Nutritional Supplementation in Elderly Patients

Conditions
-----------------
Denutrition

Intervention / Treatment
-----------------
* Dietary Supplement: Renutryl 500
* Dietary Supplement: Generique
* Dietary Supplement: Generique + Renutryl 500


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalization into a geriatric care unit age > 70 years C reactive protein > 30 mg/l 25 < albumin < 35 g/l 130 < Na < 145 mmol/l BMI < 22 weight loss > 10 % within the last 6 months MNA < 23.5 Exclusion Criteria: diabetes mellitus severe digestive failure enteral or parenteral nutrition renal,cardiac or digestive failure lactose intolerance terminal phase severe pathology MMS < 15

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: I<br> | |
| Active Comparator: II<br>oral nutrition | Dietary Supplement: Renutryl 500<br> <br> |
| Experimental: III<br>oral nutrition | Dietary Supplement: Generique<br> <br> |
| Experimental: IV<br>oral nutrition | Dietary Supplement: Generique + Renutryl 500<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nutritional Risk Index |  | At J0, J21, J42 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of body mass index (BMI), Mini Nutritional Assessment, Fat mass,lean mass, serum albumin and transthyretin,Activities of Daily Living (ADL), ingesta and morbidity. |  |  | 
| Tolerance |  | Daily | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
elderly people
Early Ultrasound and Maternal Biochemical Markers to Evaluate the Risk of Down Syndrome During the First Trimester

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the risk of Down syndrome during the first trimester of the pregnancy. The risk assessment is evaluated using early ultrasound and maternal biochemical markers.

Official Title
-----------------
Nuchal Translucency Study - PAPP-A

Conditions
-----------------
Down Syndrome

Intervention / Treatment
-----------------
* Device: echography
* Other: blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female > 18 years old Pregnant Exclusion Criteria: Maternal age < 18 years old, twin pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: echography|nan|
|Other: blood sample|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nucal translucency, Down syndrome, MSS, Risk assessment
Ministry of Child and Family Development (MCFD) Interpersonal Psychotherapy for Adolescents (IPT-A) Training Project

Study Overview
=================
Brief Summary
-----------------
Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models

Official Title
-----------------
Evaluating the Effectiveness of Different Interpersonal Psychotherapy for Adolescents (IPT-A) Therapist Training Models

Conditions
-----------------
Education of Therapists Treating Adolescent Depression

Intervention / Treatment
-----------------
* Behavioral: Psychotherapy Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -adolescent undergoing psychotherapy Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Psychotherapy Training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IPT, Depression, Adolescents, Knowledge translation, Psychotherapy